Answers are grounded in this paper and cite their sources.
Dear Editor, Epidermolysis bullosa (EB) is a group of inherited diseases characterized by recurrent skin blistering due to impaired epidermal or dermoepidermal adhesion. In some subtypes, damage to internal organs causes serious comorbidities; an increased risk of early and aggressive squamous cell carcinoma characterizes recessive dystrophic EB.1 It is likely that EB will only be cured by mutation‐correction interventions, but until that goal becomes a reality we need to pool and extend knowledge about wound management and other strategies to improve quality of life for people with EB. EB is rare, so management must be guided by expert clinical consensus and experience, and evidence derived from clinical trials where available.2 3 DEBRA International brought together researchers and clinicians from different specialties to share knowledge about the biology of wounds, effective treatments and research strategies. The objectives of the meeting, held in December 2016, were: (i) to evaluate current knowledge and challenges in EB wound healing; (ii) to develop consensus on unmet research priorities; (iii) to widen the net of experts with a view to identifying fresh concepts; and (iv) to set priorities for future research proposals. We comment here on the topics discussed and the priorities identified. A full report of the meeting may be found on the DEBRA website.4 A full list of delegates is provided in Appendix S1 (see Supporting Information). The topics discussed are summarized in Table 1. Outline of the major topics discussed at the epidermolysis bullosa (EB) Wound Healing Meeting Outline of the major topics discussed at the epidermolysis bullosa (EB) Wound Healing Meeting Collectively, the meeting delegates could provide a significant body of data on patients with EB. The establishment of a biobank of tissues (blister fluid, exudate and biopsies), with detailed clinical data and information on interventions such as dressings and topical and systemic medications, was identified as a collaborative opportunity. Correlating data with genetic information could allow investigation of genotype–phenotype relationships and identification of modifier genes. Long‐term patient data might also provide additional insight into the development of squamous cell carcinoma. Trauma is the precipitating factor for many wounds, but the natural history of the wound and its healing remain poorly understood, and further investigation into the biology at different tissue depths and across the wounds, along with their anatomical distribution is required. The oral mucosa is prone to damage in EB, but more information is needed to appreciate differences between mucosa and external skin and how scarring lower down in the gut and at other mucosal surfaces can cause strictures and other problems. Infection and inflammation are important contributors to wound progression; greater knowledge of these and their impact in patients with EB is needed. We need to understand how commensal bacteria can promote healing or prevent colonization by pathological bacteria. Specifically, data on how host inflammatory cell types and mediators affect healing and the roles of pH and ions are required. It is not clearly understood what precipitates the switch from an acute wound to a chronic wound (or a persistent nonhealing acute wound) or why some wounds heal efficiently while others follow a less predictable course – healing and relapsing. The mechanisms behind development of scar tissue also warrant further investigation. Perpetually itchy skin and pain are the most distressing symptoms for a majority of patients with EB, yet the pathways of both remain poorly understood in EB. Symptom control is a priority, so positive, practical interventions need to be identified alongside more basic and mechanistic research. Wound exudate and odour can also be problematic and the best intervention(s) need to be determined. Successful wound management remains diverse and in some cases elusive; there needs to be greater sharing of experience with different wound dressings and definition of optimal moisture balance for wound closure. ‘Smart’ dressings have been developed for burn wounds, which can indicate the presence of underlying infection – allowing the healing process to benefit from an undisturbed dressing while avoiding the complication of incipient infection. Dressings have also been developed that can carry pharmacologically active agents. Appreciating which agents are active on the surface and those that need ‘carriers’ to take them to deeper skin layers will help in exploiting these new developments to the full in EB. Burn wound research is also an advancing technology for grafting cells and tissues to promote healing. Techniques such as cell delivery by microneedles or ‘spray‐on’ cell preparations with methods of avoiding rejection are being developed5 and would warrant investigation in patients with EB. Outcome measures need to be more practical and patient centric. The much‐used end point of complete wound closure for 7 days is often not realistic; closure is not synonymous with healing, and wound cover may be achieved but followed by breakdown within a short time period.6 Significant, albeit incomplete, closure of wounds still may improve patients’ quality of life. There needs to be collaboration between patients, clinicians and regulators to define outcome measures and clinically meaningful end points in the various subtypes of EB. There remains a need for further evaluation and standardization of the tools by which we measure wound healing. Detailed photographic documentation of wounds is recorded in clinical investigations, but encouraging more frequent recording of wound progress could be beneficial. This meeting demonstrated potential opportunities for greater sharing of basic science and clinical management across specialities. A cure or cures for EB remain a long‐term goal, but pooling expertise across disciplines can facilitate more rapid improvements in wound care. Identifying and progressing incremental changes to achieve significant clinical benefit is a clear goal in supporting people living with EB. This meeting was sponsored by DEBRA International. Meeting expenses were covered but delegates were not paid an honorarium for their participation. Medical writing support was provided by Jan Hawthorn and funded by DEBRA International. The meeting was held at the British Association of Dermatologists, Fitzroy Square, London. Funding sources: DEBRA International. Conflicts of interest: none declared. Appendix S1 List of meeting delegates.
No takes yet. Share an insight, caveat, or question.
Bruckner‐Tuderman et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: